BioAge Labs (NASDAQ:BIOA) Trading Up 2.7% - Here's What Happened

Key Points

• BioAge Labs' shares rose by 2.7% to trade at $4.93 after reaching a high of $5.10, with trading volume increasing by 30% from the average.
• Analysts at Wall Street Zen have downgraded BioAge Labs from a "hold" rating to a "sell" rating, following a quarterly earnings report missing consensus estimates.
• Institutional investors are actively trading BioAge Labs, with significant recent purchases from entities such as Police & Firemen's Retirement System and MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd., indicating growing interest in the company.

Shares of BioAge Labs, Inc. (NASDAQ:BIOA - Get Free Report) traded up 2.7% on Monday . The company traded as high as $5.10 and last traded at $4.93. 166,433 shares were traded during trading, an increase of 30% from the average session volume of 127,817 shares. The stock had previously closed at $4.80.

Analyst Upgrades and Downgrades

Separately, Wall Street Zen lowered shares of BioAge Labs from a "hold" rating to a "sell" rating in a research note on Sunday, June 29th.

BioAge Labs Stock Performance

The firm has a 50 day moving average of $4.52.

BioAge Labs (NASDAQ:BIOA - Get Free Report) last posted its earnings results on Wednesday, August 6th. The company reported ($0.60) earnings per share for the quarter, missing the consensus estimate of ($0.56) by ($0.04).

Institutional Inflows and Outflows

Institutional investors have recently modified their holdings of the company. Militia Capital Partners LP acquired a new stake in shares of BioAge Labs during the 2nd quarter worth about $166,000. Bridgeway Capital Management LLC acquired a new position in BioAge Labs during the second quarter valued at approximately $217,000. Ameriprise Financial Inc. acquired a new position in BioAge Labs during the second quarter worth about $182,000. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. boosted its position in BioAge Labs by 85.6% in the second quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 12,955 shares of the company's stock valued at $54,000 after buying an additional 5,976 shares in the last quarter. Finally, Marshall Wace LLP grew its position in BioAge Labs by 324.7% during the 2nd quarter. Marshall Wace LLP now owns 226,789 shares of the company's stock worth $937,000 after acquiring an additional 173,388 shares during the last quarter.

BioAge Labs Company Profile

We are a clinical-stage biopharmaceutical company developing therapeutic product candidates for metabolic diseases, such as obesity, by targeting the biology of human aging. Our technology platform and differentiated human datasets enable us to identify promising targets based on insights into molecular changes that drive aging.